NuVasive Rating Increased to Outperform at William Blair (NUVA)
NUVA has been the subject of a number of other recent research reports. Analysts at Wells Fargo & Co. (NYSE: WFC) initiated coverage on shares of NuVasive in a research note to investors on Monday, April 9th. They set a “market perform” rating on the stock. Separately, analysts at JMP Securities upgraded shares of NuVasive from a “market perform” rating to an “outperform” rating in a research note to investors on Thursday, March 15th. They now have a $21.00 price target on the stock. Finally, analysts at Goldman Sachs (NYSE: GS) raised their price target on shares of NuVasive to $16.00 in a research note to investors on Friday, March 9th.
NuVasive traded up 3.43% on Tuesday, hitting $21.09. NuVasive has a 1-year low of $11.02 and a 1-year high of $34.91. The company’s market cap is $899.6 million.
The company last announced its quarterly results on Monday, April 30th. It reported $0.20 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.18 EPS by $0.02. The company’s quarterly revenue was up 21.8% on a year-over-year basis. Analysts expect that NuVasive will post $0.24 EPS next quarter.
NuVasive, Inc. (NuVasive) is a medical device company. NuVasive focuses on developing minimally disruptive surgical products and procedures for the spine.